Management of gram-positive bacterial infections in patients with cancer

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 8-18

  Kosmidis, Christos I ^a   Chandrasekar, Pranatharthi H ^a,b  

^a Division of Infectious Diseases   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Infectious complication neoplasia; Infectious complications marrow and stem cell transplant; Management

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPICILLIN; CARBAPENEM; CEFEPIME; CEPHALOSPORIN; CISPLATIN; COTRIMOXAZOLE; CYCLOSPORIN; CYTARABINE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUDARABINE; GENTAMICIN; IMIPENEM; LINEZOLID; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RNA 16S; STEROID; TACROLIMUS; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ABSCESS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AORTITIS; BACILLUS; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CATHETER INFECTION; CATHETER REMOVAL; CELLULITIS; CENTRAL VENOUS CATHETER; CHRONIC LYMPHATIC LEUKEMIA; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COAGULASE POSITIVE STAPHYLOCOCCUS; COLITIS; COMORBIDITY; CORYNEBACTERIUM; CREATINE KINASE BLOOD LEVEL; CYTOMEGALOVIRUS; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENDOCARDITIS; ENTEROCOCCACEAE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS AVIUM; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; FEBRILE NEUTROPENIA; GAS GANGRENE; GERIATRIC PATIENT; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAM POSITIVE INFECTION; GRANULOCYTE; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS PATIENT; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFECTION RATE; INFECTION RISK; INFORMATION RETRIEVAL; INTRAVENOUS DRUG ABUSE; LENGTH OF STAY; LEUKOPENIA; LISTERIA MONOCYTOGENES; LISTERIOSIS; LUNG INFECTION; LUNG INFILTRATE; LYMPHOMA; MENINGOENCEPHALITIS; METASTASIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MOLECULAR DIAGNOSIS; MORTALITY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MUSCLE NECROSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; NOCARDIOSIS; OPTIC NERVE DISEASE; OSTEOMYELITIS; PANOPHTHALMITIS; PATHOGENESIS; PATIENT MONITORING; PENICILLIN RESISTANCE; PERIPHERAL NEUROPATHY; PHLEBITIS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SOLID TUMOR; SPECIES IDENTIFICATION; STAPHYLOCOCCUS AUREUS; SUPPURATIVE PHLEBITIS; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; TYPHLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE; NEOPLASMS; OXAZOLIDINONES;

EID: 84855427990     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.602770     Document Type: Review

References (77)

1. Viscoli C. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Th erapy Group (IATG). Eur J Cancer 2002;38(Suppl. 4):S82-S87.
2. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-259. (Pubitemid 27364722)
3. Aksu G, Ruhi MZ, Akan H, et al. Aerobic bacterial and fungal infections in peripheral blood stem cell transplants. Bone Marrow Transplant 2001;27:201-205. (Pubitemid 32156876)
4. Gaytan-Martinez J, Mateos-Garcia E, Sanchez-Cortes E, et al. Microbiological fi ndings in febrile neutropenia. Arch Med Res 2000;31:388-392.
5. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-1110. (Pubitemid 36553108)
6. Rolston KV, Yadegarynia D, Kontoyiannis DP, et al. Th e spectrum of gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against gram-positive bacteria isolated from cancer patients. Int J Infect Dis 2006;10:223-230.
7. Tumbarello M, Spanu T, Caira M, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 2009;64:320-326.
8. R ubio M, Palau L, Vivas JR, et al. Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect Control Hosp Epidemiol 1994;15:101-104.
9. Cherif H, Kronvall G, Bjorkholm M, et al. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profi les during a 14-year period without antibacterial prophylaxis. Hematol J 2003;4:420-426. (Pubitemid 38088787)
10. Y adegarynia D, Tarrand J, Raad I, et al. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003;37:1144-1145. (Pubitemid 37323675)
11. Raad I, Kassar R, Ghannam D, et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis 2009;49:1187-1194.
12. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 1999;29:259-263. (Pubitemid 29380180)
13. G onzalez-Barca E, Carratala J, Mykietiuk A, et al. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis 2001;20:117-119. (Pubitemid 32247107)
14. Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol 2000;18:1110-1115. (Pubitemid 30123790)
15. Ghanem GA, Boktour M, Warneke C, et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 2007;86:54-60. (Pubitemid 46104920)
16. Venditti M, Falcone M, Micozzi A, et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica 2003;88:923-930. (Pubitemid 37128093)
17. B ochud PY, Eggiman P, Calandra T, et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994;18:25-31. (Pubitemid 24025915)
18. Richard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995;345:1607-1609.
19. E ngelhard D, Elishoov H, Or R, et al. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 1995;16:565-570.
20. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-1207.
21. R ingden O, Heimdahl A, Lonnqvist B, et al. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet 1984;1:744.
22. C ollin BA, Leather HL, Wingard JR, et al. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001;33: 947-953. (Pubitemid 32907094)
23. B ilgrami S, Feingold JM, Dorsky D, et al. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998;21:591-595. (Pubitemid 28138258)
24. P rabhu RM, Piper KE, Litzow MR, et al. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005;24:832-838. (Pubitemid 43042790)
25. R azonable RR, Litzow MR, Khaliq Y, et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to levofl oxacin among neutropenic patients receiving levofl oxacin prophylaxis. Clin Infect Dis 2002;34:1469-1474. (Pubitemid 34553706)
26. Guthrie KA, Yong M, Frieze D, et al. Th e impact of a change in antibacterial prophylaxis from ceftazidime to levofl oxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010;45:675 -6 81.
27. K ruger WH, Bohlius J, Cornely OA, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 2005;16:1381-1390.
28. M atar MJ, Tarrand J, Raad I, et al. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 2006;34:534-536. (Pubitemid 44479799)
29. T odeschini G, Tecchio C, Borghero C, et al. Association between Enterococcus bacteraemia and death in neutropenic patients with haematological malignancies. J Infect 2006;53:266-273. (Pubitemid 44424268)
30. V enditti M, Tarasi A, Visco Comandini U, et al. Enterococcal septicemia in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993;12:241-247. (Pubitemid 23139894)
31. Worth LJ, Th ursky KA, Seymour JF, et al. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007;79:226-233. (Pubitemid 47241068)
32. D ubberke ER, Hollands JM, Georgantopoulos P, et al. Vancomycinresistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 2006;38:813-819. (Pubitemid 44830841)
33. A very R, Kalaycio M, Pohlman B, et al. Early vancomycinresistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 2005;35:497-499. (Pubitemid 40403353)
34. Z eana, C, Kubin CJ, Della-Latta P, et al. Vancomycin-resistant enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001;33:477-82. (Pubitemid 32709579)
35. L e J, Bookstaver B, Rudisill CN, et al. Treatment of meningitis caused by vancomycin-resistant enterococcus faecium: high-dose and combination daptomycin therapy. Ann Pharmacother 2010;44:2001-2006.
36. S capellato PG, Ormazabal C, Scapellato JL, et al. Meningitis due to vancomycin-resistant enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol. J Clin Microbiol 2005;43:3578-3579. (Pubitemid 40981401)
37. A naissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fl udarabine and prednisone. Ann Intern Med 1992;117:466-469.
38. R ivero GA, Torres HA, Rolston KV, et al. Listeria monocytogenes infection in patients with cancer. Diagn Microbiol Infect Dis 2003; 47:393-398. (Pubitemid 38373410)
39. M erle-Melet M, Dossou-Gbete L, Maurer P, et al. Is amoxicillincotrimoxazole the most appropriate antibiotic regimen for Listeria meningoencephalitis? Review of 22 cases and the literature. J Infect 1996;33:79-85. (Pubitemid 26336418)
40. M ylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with Listeria monocytogenes. 33 years ' experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore) 1998;77:313-336. (Pubitemid 28449833)
41. T orres HA, Reddy BT, Raad II, et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002;81:388-397.
42. v an Burik JA, Hackman RC, Nadeem SQ, et al. Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis 1997;24:1154-1160. (Pubitemid 27249016)
43. B obak D, Arfons LM, Creger RJ, et al. Clostridium diffi cileassociated disease in human stem cell transplant recipients: coming epidemic or false alarm? Bone Marrow Transplant 2008; 42:705-713.
44. Chopra T, Salimnia H, Merline J, et al. Current epidemiology of Clostridium difficile associated disease (CDAD) in hematopoietic stem cell transplant recipients (HSCTR). Presented at 45th Annual Meeting of Infectious Diseases Society of America, 2007, San Diego, CA.
45. C hopra T, Alangaden GJ, Chandrasekar P. Clostridium diffi cile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Th er 2010;8:1113-1119.
46. B atlle M, Vall-Llovera F, Bechini J, et al. [Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases]. Med Clin (Barc) 2007;129:660-663. (Pubitemid 350256414)
47. King A, Wight DG. Clostridium septicum and neutropenic enterocolitis. Lancet 1987;2:1279.
48. Hopkins DG, Kushner JP. Clostridial species in the pathogenesis of necrotizing enterocolitis in patients with neutropenia. Am J Hematol 1983;14:289-295. (Pubitemid 13094394)
49. E l-Masry S. Spontaneous gas gangrene associated with occult carcinoma of the colon: a case report and review of literature. Int Surg 2005;90:245-247.
50. Mohamed HK, Elliott BM, Brothers TE, et al. Suprarenal Clostridium septicum aortitis with rupture and simultaneous colon cancer. Ann Vasc Surg 2006;20:825-829. (Pubitemid 46020516)
51. Mirza NN, McCloud JM, Cheetham MJ. Clostridium septicum sepsis and colorectal cancer - a reminder. World J Surg Oncol 2009;7:73.
52. Lorimer JW, Eidus LB. Invasive Clostridium septicum infection in association with colorectal carcinoma. Can J Surg 1994;37: 245-249. (Pubitemid 24246389)
53. Schickner DC, Yarkoni A, Langer P, et al. Panophthalmitis due to Clostridium septicum. Am J Ophthalmol 2004;137:942-944. (Pubitemid 38582054)
54. Chew SS, Lubowski DZ. Clostridium septicum and malignancy. ANZ J Surg 2001;71:647-649. (Pubitemid 33071024)
55. G hide S, Jiang Y, Hachem R, et al. Catheter-related Corynebacterium bacteremia: should the catheter be removed and vancomycin administered? Eur J Clin Microbiol Infect Dis 2010;29: 153-156.
56. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45.
57. Kassar R, Hachem R, Jiang Y, et al. Management of Bacillus bacteremia: the need for catheter removal. Medicine (Baltimore) 2009;88:279-283.
58. Cotton DJ, Gill VJ, Marshall DJ, et al. Clinical features and therapeutic interventions in 17 cases of Bacillus bacteremia in an immunosuppressed patient population. J Clin Microbiol 1987;25: 672-674. (Pubitemid 17041865)
59. Ramos ER, Hachem R, Youssef S, et al. Th e crucial role of catheters in micrococcal bloodstream infections in cancer patients. Infect Control Hosp Epidemiol 2009;30:83-85.
60. K uderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266. (Pubitemid 43673249)
61. Mustafa MM, Carlson L, Tkaczewski I, et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001;20:362-369. (Pubitemid 32240289)
62. H ughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751. (Pubitemid 34194843)
63. S akoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to effi cacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402. (Pubitemid 38747480)
64. Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-327.
65. Morris A, Ward C. High incidence of vancomycin-associated leucopenia and neutropenia in a cardiothoracic surgical unit. J Infect 1991;22:217-223.
66. H ope R, Livermore DM, Brick G, et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008;62(Suppl. 2):ii65 - ii74.
67. H ahn-Ast C, Glasmacher A, Arns A, et al. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant? Infection 2008;36: 54-58.
68. C how AW, Jewesson PJ, Kureishi A, et al. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol Suppl 1993;54:18-24. (Pubitemid 23224529)
69. Z iglam HM, Gelly K, Olver W. A survey of the management of neutropenic fever in oncology units in the UK. Int J Antimicrob Agents 2007;29:430-433. (Pubitemid 46357610)
70. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, doubleblind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597-607. (Pubitemid 43271371)
71. R olston KV, McConnell SA, Brown J, et al. Daptomycin use in neutropenic patients with gram-positive bacteremia. Blood 2008;112(Suppl. 1): Abstract 1475.
72. S akoulas G. Daptomycin for soft tissue infection and neutropenia in a myelogenous leukemia patient who failed prior vancomycin therapy. Clin Adv Hematol Oncol 2008;6:813-815.
73. P outsiaka DD, Skiffi ngton S, Miller KB, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54:567-571. (Pubitemid 46731225)
74. Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 2009;53:428-434.
75. L ong JK, Choueiri TK, Hall GS, et al. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 2005;80:1215-1216. (Pubitemid 41233359)
76. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 2009;88:211-220.
77. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009;49:1908-1914.